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Background-—The optimal timing to administer non–vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and
atrial fibrillation is unclear. This prospective observational multicenter study evaluated the rates of early recurrence and major bleeding
(within90 days)andtheirtiminginpatientswithacuteischemicstrokeandatrialfibrillationwhoreceivedNOACsforsecondaryprevention.
Methods and Results-—Recurrence was defined as the composite of ischemic stroke, transient ischemic attack, and symptomatic
systemic embolism, and major bleeding was defined as symptomatic cerebral and major extracranial bleeding. For the analysis,
1127 patients were eligible: 381 (33.8%) were treated with dabigatran, 366 (32.5%) with rivaroxaban, and 380 (33.7%) with
apixaban. Patients who received dabigatran were younger and had lower admission National Institutes of Health Stroke Scale score
and less commonly had a CHA2DS2-VASc score >4 and less reduced renal function. Thirty-two patients (2.8%) had early recurrence,
and 27 (2.4%) had major bleeding. The rates of early recurrence and major bleeding were, respectively, 1.8% and 0.5% in patients
receiving dabigatran, 1.6% and 2.5% in those receiving rivaroxaban, and 4.0% and 2.9% in those receiving apixaban. Patients who
initiated NOACs within 2 days after acute stroke had a composite rate of recurrence and major bleeding of 12.4%; composite rates
were 2.1% for those who initiated NOACs between 3 and 14 days and 9.1% for those who initiated >14 days after acute stroke.
Conclusions-—In patients with acute ischemic stroke and atrial fibrillation, treatment with NOACs was associated with a combined
5% rate of ischemic embolic recurrence and severe bleeding within 90 days. ( J Am Heart Assoc. 2017;6:e007034. DOI: 10.
1161/JAHA.117.007034.)
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P atients with acute ischemic stroke and nonvalvular atrialfibrillation (AF) are at high risk of early recurrence.1,2 In
these patients, anticoagulant therapy plays a major role in the
prevention of recurrent ischemic stroke. Because early
hemorrhagic transformation is a major concern, the optimal
time to start anticoagulant therapy remains a controversial
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issue. Indeed, there are no comparative randomized studies
on the optimal timing of the start of anticoagulation in
patients with acute ischemic stroke and nonvalvular AF. Thus,
such a decision hinges on the assessment of the competing
risks of early thromboembolic recurrences and hemorrhagic
transformation.3 Data from the RAF (Early Recurrence and
Cerebral Bleeding in Patients With Acute Ischemic Stroke and
Atrial Fibrillation) study suggested that the optimal time for
initiating anticoagulation treatment for secondary stroke
prevention may be 4 to 14 days from stroke onset.4
Moreover, patients treated with oral anticoagulants alone
had better outcomes compared with patients treated with
low-molecular-weight heparins (LMWHs) alone or before oral
anticoagulants. In the RAF study, with enrollment from
January 2012 to March 2014, <10% of the patients were
treated with non–vitamin K oral anticoagulants (NOACs).4
Observational studies reported that, if NOACs are started
early after an index event, the risk of intracranial bleeding
appears to be low.5–7
This international, prospective, observational, multicenter
study in patients with acute stroke and AF treated with
NOACs for secondary prevention evaluated, at 90 days from
the acute event, (1) the rates of recurrent ischemic embolic
event and severe bleeding (both intra- and extracranial) and
their timing and (2) the risk factors associated with ischemic
stroke recurrence, systemic embolism, symptomatic cerebral
bleeding, and severe extracerebral hemorrhage.
Methods
The RAF-NOACs (Early Recurrence and Major Bleeding in
Patients With Acute Ischemic Stroke and Atrial Fibrillation
Treated With Non–Vitamin K Oral Anticoagulants) study was a
prospective observational study carried out between April
2014 and June 2016 that enrolled consecutive patients with
acute ischemic stroke and known or newly diagnosed AF who
did not have contraindications to anticoagulation with NOACs.
As exclusion criteria, we considered 1) high risk of bleeding,
defined as clinically significant liver disease (acute or chronic
hepatitis, cirrhosis, or alanine aminotransferase level >3 times
the upper limit of normal), creatinine clearance <30 mL/min
(for apixaban, the threshold was 25 mL/min), 2) life
expectancy of <3 to 6 months, 3) use of interacting
medications, and 4) uncontrolled hypertension. The study
was performed in 35 stroke units across Europe, the United
States, and Asia. The study was approved by the local
institutional review boards, if required. Patient consent was
obtained from either the patient or a family member (e.g. in
aphasic patient).
On admission, stroke severity was assessed using the
National Institutes of Health Stroke Scale (NIHSS). A
noncontrast cerebral computed tomography (CT) or cerebral
magnetic resonance imaging (MRI) scan was performed on
admission in all patients to exclude intracranial hemorrhage.
Thrombolysis treatment was given as per standard local
protocol, if appropriate. Standard stroke unit care, monitoring,
and treatment were provided by all participating centers
according to current international recommendations for acute
ischemic stroke.8–10 All patients were monitored for blood
pressure, temperature, glucose level, and heart rate in the
first days after stroke. Attending physicians were free to make
decisions about the type of anticoagulant to be used for
secondary prevention and the day on which to initiate it;
however, in this article, we report only patients who received
a NOAC.
Nonvalvular AF was classified as paroxysmal (episodes
terminating spontaneously within 7 days), persistent (epi-
sodes lasting >7 days requiring pharmacologic and/or elec-
trical stimulation), or permanent (persisting for >1 year, either
because cardioversion failed or was not attempted).11
A second brain CT scan or MRI had to be performed 24 to
72 hours from stroke onset in all patients. Hemorrhagic
transformation (HT) was defined on CT scan as any degree of
hyperdensity within the area of low attenuation and was
classified as either hemorrhagic infarction or parenchymal
hematoma.12,13 On MRI, HT was defined as hypointensity on
axial T1- and T2-weighted images. HT was considered
symptomatic if associated with a decline in neurological
status (an increase of ≥4 points in NIHSS score) in the
absence of any bleeding evidence on the first CT.14 The sites
and sizes of the qualifying infarcts were determined based on
standard templates15,16: (1) Small lesions were ≤1.5 cm in
the anterior or posterior circulation; (2) medium lesions were
in a cortical superficial branch of the middle cerebral artery
(MCA), in the MCA deep branch, in the internal border zone
Clinical Perspective
What Is New?
• This study evaluated the rates of both recurrence and major
bleeding within 90 days in patients with acute ischemic
stroke and atrial fibrillation who were prescribed non–
vitamin K oral anticoagulants for secondary prevention; the
results showed a combined 5.2% rate of ischemic embolic
recurrence (2.8%) and severe bleeding (2.4%).
• Overall, 80% of the patients received non–vitamin K oral
anticoagulants within 15 days of the index stroke.
What Are the Clinical Implications?
• Non–vitamin K oral anticoagulants could be used within
2 weeks from stroke onset, given the seemingly acceptable
risk of severe bleeding.
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Table 1. Characteristics of the Treatment Groups
Total (N=1161) Dabigatran (n=395) Apixaban (n=390) Rivaroxaban (n=376)
Age, y 75.69.9 73.610.2* 77.29.2 76.09.7
Sex, male 542 (46.8) 209 (52.9)* 171 (44.1) 162 (43.1)
NIHSS on admission 7.76.2 6.95.0* 7.86.2 8.36.6
Diabetes mellitus 225 (19.4) 74 (18.7) 66 (17.0) 85 (22.6)
Hypertension 889 (76.5) 302 (76.4) 285 (73.1)* 302 (80.3)
Hyperlipidemia 410 (35.4) 165 (41.8) 113 (29.1)* 132 (35.1)
Atrial fibrillation†
Paroxysmal 567 (50.3) 184 (47.0) 192 (51.3) 189 (52.8)
Permanent 391 (34.8) 151 (38.3) 119 (32.2) 121 (33.8)
Persistent 167 (14.9) 58 (14.7) 61 (16.5) 48 (13.4)
History stroke/TIA 304 (26.0) 117 (29.6) 97 (24.5) 90 (23.9)
Current smoker 129 (11.1) 54 (13.7) 31 (8.0) 44 (11.7)
Alcoholism 72 (6.2) 29 (7.3) 20 (5.2) 23 (6.1)
History congestive heart failure 181 (15.6) 66 (16.7) 57 (14.7) 58 (15.4)
History myocardial infarction 134 (11.5) 39 (9.9) 43 (11.1) 52 (13.8)
History peripheral artery disease 92 (7.9) 29 (7.3) 30 (7.8) 32 (8.5)
Pacemaker 65 (5.6) 25 (6.3) 22 (5.7) 18 (4.8)
Lesion size‡
Small 448 (40.9) 147 (40.5) 162 (42.1) 140 (40.0)
Medium 388 (33.3) 131 (36.1) 138 (35.3) 120 (31.9)
Large anterior 180 (15.5) 44 (12.1)* 67 (17.4) 70 (20.0)
Large posterior 76 (6.6) 33 (9.1) 20 (5.2) 21 (6.0)
Leukoaraiosis 673 (58.0) 196 (49.6)* 258 (66.5) 220 (58.5)
Atrial enlargement§ 703 (72.0) 207 (65.5)* 256 (76.0) 241 (74.4)
Severe 161 (16.5) 45 (14.2) 56 (17.0) 58 (17.9)
Systemic thrombolysis (rtPA) 317 (27.3) 94 (23.8)* 110 (28.1) 114 (30.3)
Embolectomy 47 (4.1) 23 (5.8) 14 (3.6) 10 (2.6)
Combination rtPA plus thrombectomy 69 (6.0) 28 (7.0) 16 (4.1) 25 (6.6)
LMWH before oral anticoagulants 111 (9.6) 36 (9.1) 34 (8.8) 41 (10.9)
Hemorrhagic transformation at 24–72 h 106 (9.1) 37 (9.4) 37 (9.5) 32 (8.5)
Creatinine clearance, mL/min 76.617.1 93.729.3* 68.724.3 70.125.3
CHA2DS2-VASc score after index stroke
2 33 (2.8) 16 (4.0)* 10 (2.6) 7 (1.9)
3 87 (7.5) 40 (10.7) 24 (6.2) 23 (6.1)
4 177 (15.4) 89 (22.5) 48 (12.4) 40 (10.6)
5 311 (26.8) 97 (24.5) 114 (29.3) 100 (26.6)
6 358 (30.7) 97 (24.5) 126 (32.0) 136 (36.2)
7 152 (13.2) 40 (10.2) 54 (13.9) 58 (15.4)
8 35 (3.0) 11 (2.8) 13 (3.4) 11 (2.9)
9 7 (0.6) 5 (1.3) 1 (0.2) 1 (0.3)
>4 863 (74.3) 250 (63.3)* 309 (78.9) 306 (81.4)
Data are shown as meanSD or n (%).LMWH indicates low-molecular-weight heparin; NIHSS, National Institutes of Health Stroke Scale; rtPA, recombinant tissue plasminogen activator;
TIA, transient ischemic attack.
*P<0.05.
†1123 patients.
‡1096 patients.
§976 patients with transthoracic echocardiogram performed.
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territories, in a cortical superficial branch of the posterior
cerebral artery, or in a cortical superficial branch of the
anterior cerebral artery; (3) large anterior lesions involved the
complete territory of the MCA, posterior cerebral artery, or
anterior cerebral artery or were in 2 cortical superficial
branches of the MCA, in a cortical superficial branch of MCA
associated with the MCA deep branch, or in >1 artery territory
(eg, MCA associated with anterior cerebral artery territory); (4)
large posterior lesions were ≥1.5 cm in the brain stem or
cerebellum.13
Risk Factors
Data on known stroke risk factors were collected, as
described previously2: age, gender, history of hypertension
(blood pressure ≥140/90 mm Hg at least twice before stroke
or already under treatment with antihypertensive drugs),
history of diabetes mellitus (fasting glucose level ≥126 mg/
dL preprandial on 2 examinations, glucose level ≥200 mg/dL
postprandial, HbA1c ≥6.5%, or under antidiabetic treatment),
current cigarette smoking, past smoking (cessation <5 years
earlier), hyperlipidemia (total cholesterol ≥200 mg/dL, triglyc-
eride ≥140 mg/dL, or already under lipid-lowering therapy),
history of symptomatic ischemic heart disease (myocardial
infarction, history of angina or existence of multiple lesions on
thallium heart isotope scan, or evidence of coronary disease
on coronary angiography), history of symptomatic peripheral
arterial disease (intermittent claudication of presumed
atherosclerotic origin; ankle/arm systolic blood pressure
ratio <0.85 in either leg at rest; or history of intermittent
claudication with previous leg amputation, reconstructive
surgery, or angioplasty), alcohol abuse (≥300 g/week), obe-
sity (body mass index ≥30), or previous stroke or transient
ischemic attack [TIA]). White matter changes (leukoaraiosis
defined on the first CT [or MRI] examination as ill-defined and
moderately hypodense [or hyperintensity on T2-weighted MRI]
areas of ≥5 mm, according to published criteria) were
investigated.17 Leukoaraiosis in the deep white matter was
dichotomized into absent versus mild, moderate, or severe.
Other baseline variables obtained at admission for all patients
included fasting serum glucose, fasting serum cholesterol
(total, high-, and low-density lipoprotein), platelet count,
international normalized ratios, activated partial thromboplas-
tin time, systolic blood pressure, and diastolic blood pressure.
Data on the use of any antiplatelet, anticoagulant, or
thrombolytic agent before admission, at baseline, and during
the follow-up period were recorded.
The CHA2DS2-VASc score was calculated for the periods
before and after the index event.18
Evaluation of Outcome
Patients were followed up prospectively by face-to-face or
telephone interviews. Study outcomes at 90 days were (1)
recurrent ischemic cerebrovascular events (stroke or TIA) and
symptomatic systemic embolisms and (2) symptomatic cere-
bral bleeding and major extracerebral bleeding.
The primary study outcome was the composite of stroke,
TIA, symptomatic systemic embolism, symptomatic cerebral
bleeding, and major extracerebral bleeding.4
HTs found on neuroimaging 24 to 72 hours after onset
were not considered outcome events unless classified as
symptomatic.
Stroke was defined as the sudden onset of a new focal
neurological deficit of vascular origin in a site consistent with
the territory of a major cerebral artery and categorized as
ischemic or hemorrhagic. TIA was defined as a transient
episode of neurological dysfunction caused by focal brain
Table 2. Observed Study Outcome Events
Total (N=1127) Dabigatran (n=381) Apixaban (n=380) Rivaroxaban (n=366)
Combined end point* 59 (5.2) 11 (2.9) 28 (7.4) 20 (5.5)
Ischemic stroke 22 (2.0) 5 (1.3) 10 (2.6) 7 (1.9)
Symptomatic hemorrhagic transformation 18 (1.6) 3 (0.8) 7 (1.9) 8 (2.2)
Ischemic stroke, TIA, or systemic embolism 32 (2.8) 7 (1.8) 16 (4.2) 9 (2.4)
TIA 7 (0.6) 2 (0.5) 3 (0.8) 2 (0.5)
Systemic embolism 3 (0.3) 0 3 (0.8) 0
Symptomatic hemorrhagic transformation, severe extracranial bleeding 27 (2.4) 4 (1.0) 12 (3.2) 11 (3.0)
Serious extracranial bleeding 10 (0.9) 1 (0.2) 5 (1.3) 4 (1.1)
mRS ≥3 at 90 d 312 (27.7) 84 (22.0) 111 (31.9) 116 (31.7)
Mortality at 90 d 26 (2.3) 7 (1.8) 9 (2.4) 11 (3.0)
Data are shown as n (%). mRS indicates modified Rankin Scale; TIA, transient ischemic attack.
*Combined end point: symptomatic hemorrhagic transformation, ischemic stroke, transient ischemic attack (TIA), systemic embolism and severe extracranial bleeding.
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ischemia without acute infarction. Systemic embolism was
defined as an acute vascular occlusion of an extremity or
organ confirmed by imaging, surgery, or autopsy. Cerebral
bleeding was considered symptomatic if associated with a
decline in neurological status (an increase of ≥4 points in
NIHSS score or leading to death). Major extracerebral
bleeding was defined as a reduction in the hemoglobin level
of at least 2 g/dL, requisite blood transfusion of at least 2 U,
or symptomatic bleeding in a critical area or organ.19
Disability andmortality at 90 days were also assessed using
the modified Rankin scale. Nondisabling functional outcome
was defined as a modified Rankin scale score of 0 to 2.
Sample Size Calculation
To perform logistic regression analysis, at least 10 to 20
patients were needed for each variable included in the model.
In this study, 60 variables were to be evaluated. Conse-
quently, we anticipated the inclusion in the study of at least
1000 patients.
Statistical Analyses
Differences in the characteristics of patients with or without
outcome events were tested using the v2 test. Specifically,
univariate tests were applied to compare both clinical
characteristics on admission and preexisting risk factors for
stroke. Logistic regression models were estimated to identify
relevant predictors for outcome events20: combined ischemic
and hemorrhagic, ischemic, and hemorrhagic. The variables
included in the model were those reaching significance on
univariate analysis <0.1 selected from risk factors, reperfu-
sion therapies, admission NIHSS scores, admission antithrom-
botic treatment, CHA2DS2-VASc scores, and sizes of the
ischemic lesions. The day of starting anticoagulant treatment
was inserted into the models as either a continuous or
dichotomized categorical variable. To avoid separation in the
data and biased parameter estimates in the standard logistic
models, given the low number of outcome events recorded,
the Firth method of penalized likelihood was performed.21 The
Figure 1. Cumulative probability of a first outcome event within
90 days from the index stroke.
Table 3. Characteristics of Patients With and Without
Outcome Events
With Events
(n=59)
Without
Events
(n=1068) P Value
Age, y 75.59.9 76.89.1
Sex, male 30 (46.8) 483 (45.2)
NIHSS on admission 7.66.1 8.27.0
Diabetes mellitus 18 (30.5) 196 (18.3) 0.02
Hypertension 49 (83.0) 802 (75.1)
Hyperlipidemia 22 (37.3) 378 (35.4)
Atrial fibrillation*
Paroxysmal 23 (39.0) 520 (51.1)
Permanent 31 (52.5) 340 (33.4) 0.03
Persistent 5 (8.5) 158 (15.5) 0.05
History stroke/TIA 16 (27.1) 275 (25.7)
Current smoker 10 (16.9) 197 (18.4)
Alcoholism 4 (6.8) 65 (6.1)
History congestive heart failure 10 (16.9) 163 (15.3)
History myocardial infarction 9 (15.2) 116 (10.9)
History peripheral artery disease 6 (10.2) 78 (7.3)
Pacemaker 3 (5.1) 58 (5.4)
Lesion size†
Small 19 (32.2) 413 (38.7)
Leukoaraiosis 38 (64.4) 600 (56.2)
Atrial enlargement‡ 37 (62.7) 642 (68.2)
Moderate/severe 18 (30.5) 361 (38.3)
Systemic thrombolysis (rtPA) 13 (22.0) 293 (27.4)
Embolectomy 3 (5.1) 44 (4.1)
Combination rtPA plus
embolectomy
4 (6.8) 64 (6.0)
Antiplatelets on admission 36 (61.0) 663 (62.1)
LMWH before oral anticoagulants 13 (22.0) 97 (9.1) 0.003
Hemorrhagic transformation
at 24–72 h
7 (11.9) 95 (8.9)
CHA2DS2-VASc score after index stroke
>4 47 (79.7) 791 (74.1)
Data are shown as meanSD or n (%). LMWH indicates low-molecular-weight heparin;
NIHSS, National Institutes of Health Stroke Scale; rtPA, recombinant tissue plasminogen
activator; TIA, transient ischemic attack.
*1018 patients.
†1063 patients.
‡942 patients with trans-thoracic echocardiogram performed.
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confidence intervals (CIs) for the odds ratios (OR) were
calculated using penalized likelihood profiles.
Survival function and empirical cumulative hazards func-
tion were estimated via the Kaplan–Meier estimator for
various groups of patients; differences between functions
were tested using the log-rank test. Patients were censored at
the time of an outcome event, at death, or if they were lost to
follow-up.22
Furthermore, we estimated additional multivariate models
to investigate possible effects of predictor variables (eg,
lesion size) on the occurrence of an outcome event, for different timing of NOAC administration (<3, 3–7, 7–14,
≥15 days). These results were reported as an OR with a 95%
CI, for which a 2-sided P<0.05 was considered significant.
All statistical analyses were performed using the software
R version 3.0.3 (R Foundation for Statistical Computing).
Results
Overall, 1161 consecutive patients were included in the study
(mean age 75.69.9 years). Of these, 34 patients were
excluded for incomplete follow-up data, leaving 1127 patients
for the analysis (Table 1).
After the acute stroke, 395 patients (34.0%) were treated
with dabigatran (189 with 300 mg/day), 390 (33.6%) with
rivaroxaban (244 with 20 mg/day), and 376 (32.4%) with
apixaban (261 with 10 mg/day). Before treatment
with NOACs, 728 patients (62.7%) received antiplatelet
agents, and 111 patients (9.6%) received full-dose LMWH. In
addition 25 patients (2.2%) were treated with NOACs
concurrently with antiplatelet agents.
Patients who received dabigatran were significantly
younger and had significantly lower NIHSS scores on
Figure 2. Combined risks of outcome events (ischemic and
hemorrhagic) depending on the time between onset and initiation
of therapy with non–vitamin K oral anticoagulants (NOACs). The
lower risk of the combined outcome event was within 14 days.
Figure 3. Risks of outcome events depending on the time
between onset and initiation of therapy with non–vitamin K oral
anticoagulants (NOACs).
Table 4. Mean Latencies (Days) From Start of NOAC
Treatment at Different Time Points After Stroke Onset
Time Intervals Mean Quartile 1 Median Quartile 3
Combined (ischemic and hemorrhagic) outcome events, d
<3 26.4 3.25 20.5 53.0
3–7 25.9 7.75 17.0 35.5
8–14 33.7 5.5 13.0 64.5
≥15 33.9 11.0 29.0 51.5
Overall combined
outcomes
29.2 6.75 17.0 52.75
Ischemic outcome events, d
<3 28.8 4.0 31.0 52.0
3–7 32.4 17.0 20.0 43.5
8–14 30.0 5.5 11.0 45.0
≥15 26.3 20.0 29.0 34.0
Overall ischemic
outcomes
30.4 12.0 22.5 45.75
Hemorrhagic outcome events, d
<3 31.0 7.75 33.0 56.25
3–7 15.9 5.0 7.0 12.0
8–14 35.1 6.25 27.5 59.75
≥15 33.8 11.0 11.0 64.0
Overall hemorrhagic
outcomes
28.5 5.5 11.0 56.25
NOACs indicates non–vitamin K oral anticoagulants.
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admission and, less commonly, had CHA2DS2-VASc scores >4
and reduced renal function (Table 1).
HT on neuroimaging performed 24 to 72 hours after stroke
onset was identify in 106 patients (9.1%): 77 (6.6%) had
hemorrhagic infarction, and 29 (2.5%) had parenchymal
hematoma.
At 90 days, 312 (27.7%) patients were deceased or
disabled (modified Rankin scale score ≥3); of those, 26
(2.3%) were deceased.
Rates of Recurrent Ischemic Events or Bleeding
Of the 1127 patients available for the final analysis, 59 (5.2%)
had outcome events: 32 (2.8%) had ischemic stroke, TIA, or
systemic embolism, and 27 (2.4%) had symptomatic intracra-
nial bleeding or major extracerebral bleeding (Table 2 and
Figure 1).Mean latency from index stroke to recurrent ischemic
event (stroke, TIA, systemic embolism) was 23.227.4 days
(median: 17 days; interquartile range [IQR]: 2–39 days) and to
severe bleeding was 18.130.7 days (median: 7 days; IQR:2
to 42 days). The characteristics of patients with and without
outcome events are reported in Table 3.
Poststroke Anticoagulation and the Risk of
Recurrent Ischemic Events or Bleeding
The analysis that evaluated the rates of the primary study
outcome associated with the day of initiating anticoagulant
treatment is reported in Figure 2. Primary outcome events
were experienced by 12.4% (95% CI, 7.4–17.4%; 19/153) of
patients who initiated NOACs within 2 days from the index
stroke, 2.1% (95% CI, 1.1–3.1%; 15/710) who initiated NOACs
between 3 and 14 days, and 9.1% (95% CI, 6.1–12.1%; 24/
264) who initiated NOACs after 14 days (P<0.0001). Figure 3
reports the rates of ischemic or hemorrhagic outcome events
associated with the day of initiating anticoagulant treatment.
Despite the occurrences of outcome events having variability
with respect to the timing of NOAC administration, the results
from the multivariate model suggested no significant marginal
effect regarding the timing of administration (within 3 days
Table 5. Characteristics of the Patients Treated With Low or
High Dose of NOACs
Low Dose
(n=467)
High Dose
(n=694) P Value
Age, y 82.0 (71–93) 74.0 (63–85) 0.0001
Sex, male 190 (40.7) 352 (50.7) 0.001
NIHSS on admission 7.0 (2 to 16) 5.0 (2 to 12) 0.013
Diabetes mellitus 99 (21.2) 125 (18.0)
Hypertension 387 (82.9) 503 (72.5) 0.0001
Hyperlipidemia 168 (36.0) 242 (34.9)
Current smoker 32 (6.9) 99 (14.3) 0.0001
Alcoholism 28 (6.0) 45 (6.5)
Lesion size*
Small 161 (37.6) 289 (43.3) 0.06
Large anterior 82 (19.2) 98 (14.7) 0.05
Leukoaraiosis 299 (64.) 377 (54.3) 0.001
Creatinine clearance,
mL/min
60.5 (27.5–93.5) 74.0 (46–102) 0.02
End point events
Combined end point 21 (4.5) 38 (5.4)
Ischemic recurrence 13 (2.8) 19 (2.7)
Hemorrhagic event 8 (1.7) 19 (2.7)
Data are shown as median (interquartile range) or n (%). NIHSS indicates National
Institutes of Health Stroke Scale; NOACs, non–vitamin K oral anticoagulants.
*1094 patients.
Table 6. Outcome Events in the Dabigatran, Rivaroxaban, and Apixaban Groups After Initiating Anticoagulants
Dabigatran (n=381) Apixaban (n=380) Rivaroxaban (n=366)
Combined end point* 9 (2.4) 26 (6.9) 15 (4.1.)
Stroke, TIA, or systemic embolism 7 (1.8) 15 (4.0) 6 (1.6)
Symptomatic hemorrhagic transformation,
severe extracranial bleeding
2 (0.5) 11 (2.9) 9 (2.5)
Symptomatic hemorrhagic transformation 2 (0.5) 6 (1.6) 5 (1.4)
Ischemic stroke 5 (1.3) 9 (2.4) 4 (1.1)
TIA 2 (0.5) 3 (0.8) 2 (0.5)
Systemic embolism 0 3 (0.8) 0
Serious extracranial bleeding 0 5 (1.3) 4 (1.1)
Data are shown as n (%). TIA indicates transient ischemic attack.
* Combined endpoint: symptomatic hemorrhagic transformation, ischemic stroke, transient ischemic attack (TIA), systemic embolism and severe extracranial bleeding.
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from index stroke as reference: between 3 and 7 days: OR:
1.30; 95% CI, 0.54–3.71; between 8 and 14 days: OR: 1.44;
95% CI, 0.36–3.02; >14 days: OR: 0.59; 95% CI, 0.15–1.95).
Mean latencies from the start of NOAC treatment at different
time points after stroke onset are reported in Table 4.
In Table 5 we reported the characteristics of the patients
treated with low and high doses of direct oral anticoagulants;
patients treated with low doses were older and had lower
clearance of creatinine; furthermore, patients treated with low
doses had more large lesions than patients treated with high
doses. The risk of outcome events was similar in the groups
treated with low and high doses of direct oral anticoagulants.
Type of Anticoagulant Administered and Risk of
Recurrent Ischemic Events or Bleeding
Nine of the 381 patients who received dabigatran had an
outcome event after initiation of therapy (2.4%; 95% CI, 1.4–
3.4%), as did 15 of the 366 (4.1%; 95% CI, 2.1–6.1%) who
received rivaroxaban and 26 of the 380 (6.9%; 95% CI, 3.9–
9.9%) who received apixaban (Table 6). The rates of early
recurrence and major bleeding were 1.8% (95% CI, 0.8–2.8%)
and 0.5% (95% CI, 0.2% to 0.7%), respectively, in patients
who received dabigatran; 1.6% (95% CI, 0.6–2.6%) and 2.5%
(95% CI 2.5–3.5%), respectively, in those who received
rivaroxaban; and 4.0% (95% CI, 2.0–6.0%) and 2.9% (95% CI,
1.9–3.9%), respectively, in those who received apixaban
(Figures 4 and 5). The mean times of starting treatment from
the index events were 12.813.8 days (median: 8 days; IQR:
3–14 days) for patients treated with dabigatran,
11.111.7 days (median: 8 days; IQR: 4–14 days) for
patients treated with rivaroxaban, and 11.012.5 days
(median: 7 days; IQR: 3–14 days) for patients treated with
apixaban (Figure 6). Overall, 80% of the patients received
NOACs within 15 days from the index stroke.
Figure 4. Cumulative risksof the combinedendpoint (ischemic and
hemorrhagic) for individual non–vitamin K oral anticoagulants.
Figure 5. Cumulative risks of the ischemic or hemorrhagic end point for the non–vitamin K oral
anticoagulants.
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Risk Factors Associated With the Risk of
Recurrent Ischemic Events or Bleeding
The rates of outcome events (ischemic or hemorrhagic) within
90 days increased with rising CHA2DS2-VASc scores: Event
rates were 3.3% for patients with scores of 2 and 3, 3.0% for
those with a score of 4, 4.0% for those with a score of 5, 6.0%
for those with a score of 6, and 7.6% for those with scores of
7, 8, or 9 (P for trend 0.05).
About 12% of the patients treated with LMWH before oral
anticoagulants had an outcome event compared with 4.4% of
those treated with NOACs alone; the rates of bleeding events
were 7.3% and 1.9% in the 2 groups, respectively (P=0.0001;
Figure 7). The characteristics of the patients treated or not
with LMWH before oral anticoagulants are reported in Table 7.
There was a nonsignificant trend for small lesion size to be
inversely associated with rates of study hemorrhagic outcome
events within 90 days (Figure 8). Table 8 summarizes the
study outcome events according to lesion size.
Regarding the composite primary study outcome, the
following variables were included in the multivariate analysis
model: diabetes mellitus, history of hypertension, presence of
leukoaraiosis, LMWH preceding oral anticoagulants, and
CHA2DS2-VASc score. LMWH preceding oral anticoagulants
was predictive factor for the composite primary study
outcome event (OR: 4.13; 95% CI, 1.73–8.96; P=0.0003).
High poststroke CHA2DS2-VASc score, as a continuous
variable, was not significantly associated with the composite
primary study outcome event (OR: 1.23; 95% CI, 0.96–1.60;
P=0.09); neither was presence of leukoaraiosis (OR: 1.29;
95% CI, 0.61–2.5; P=0.5), diabetes mellitus (OR: 1.61; 95% CI,
0.80–3.23; P=0.12), or history of hypertension (OR: 1.45; 95%
CI, 0.63–3.37; P=0.37).
Regarding the ischemic outcome events, the following
variables were included in the multivariate analysis model:
paroxysmal AF, LMWH preceding oral anticoagulants, and
CHA2DS2-VASc score. LMWH preceding oral anticoagulants
was associated with the risk of ischemic events (OR: 3.73;
95% CI, 0.95–10.63; P=0.01); paroxysmal AF (OR: 0.62; 95%
CI, 0.29–1.34; P=0.2) and CHA2DS2-VASc score (OR: 1.32;
95% CI, 0.94–1.89; P=0.08) were not associated with
ischemic events.
Figure 6. Time of initiating therapy for non–vitamin K oral
anticoagulants.
Figure 7. Cumulative risks of patients treated with low-molecular-weight heparin (LMWH)
before non–vitamin K oral anticoagulants (NOACs) vs patients treated with NOACs alone.
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Regarding the hemorrhagic outcome events, the following
variables were included in the multivariate analysis model:
LMWH preceding oral anticoagulants, lesion size, leukoaraio-
sis, age, antiplatelet therapy on admission, and CHA2DS2-
VASc score. LMWH preceding oral anticoagulants was
associated with the risk of symptomatic hemorrhagic trans-
formation and severe extracranial bleeding (OR: 4.75; 95% CI,
1.60–12.32; P=0.0009). The presence of leukoaraiosis was
not significantly associated with hemorrhagic events (OR:
1.24; 95% CI, 0.46–4.04; P=0.65); neither were age (OR: 1.03;
95% CI, 0.98–1.09; P=0.2), CHA2DS2-VASc score (OR: 1.11;
95% CI, 0.80–1.59; P=0.5), the presence of a small lesion (OR:
0.71; 95% CI, 0.24–1.81; P=0.46), or therapy with antiplatelet
agents on admission (OR: 1.96; 95% CI, 0.76–5.07; P=0.1).
Discussion
In the RAF-NOACs study, patients with acute stroke and AF
treated with NOACs had a 90-day rate of 2.8% for recurrent
ischemic stroke or TIA and 1.6% for symptomatic cerebral
bleeding; the large majority of patients received NOACs within
15 days. In the current study, the rates of ischemic and
hemorrhagic outcome events were 60% lower than in the RAF
study that included mainly patients treated with vitamin K
antagonists.4
A recent prospective cohort study reported that, despite
the early start of NOACs (65% of the 155 included patients
received therapy within 7 days), no intracerebral hemorrhage
occurred and 4 patients had recurrent ischemic stroke during
follow-up.7 In the study by Seiffge et al,7 11% of the patients
had TIA as index event, and the median NIHSS score on
admission was 4 compared with 6 in the RAF-NOACs study, in
which all patients had ischemic stroke. The differences in
underlying stroke severity and inclusion criteria in our study
may account for the discrepancies in the rates of hemorrhagic
events between these 2 studies. It is noteworthy that the
efficacy and safety of starting NOACs within 14 days after an
acute stroke have not been evaluated in the existing pivotal
randomized clinical trials because of their inclusion criteria:
Apixaban was to be started at least 7 days after ischemic
stroke, whereas rivaroxaban and dabigatran were to be
initiated at least 14 days after stroke.23–25 The greatly
elevated underlying rate of events likely partly explains the
nonsignificantly higher event rates observed if NOACs were
initiated within 2 days versus 3 to 14 days after stroke onset.
Another reason for higher hemorrhage rates among patients
starting anticoagulants early relates to the timing of routine
repeated imaging: Evidence of asymptomatic bleeding will
inevitably be detected by routine scans, which are conducted
especially within the first 48 hours after the index stroke.
The optimal time to start anticoagulation is often chosen
based on the size of the lesion, which is considered the major
risk factor for HT. In fact, in the RAF study, multivariate
analysis revealed that large lesions were associated with
elevated rates of the composite of symptomatic cerebral
bleeding and stroke recurrence but did not demonstrate a
difference from smaller lesions in the relative proportions of
recurrence and bleeding. In the current study, however, we
found a trend toward fewer ischemic events but similar rates
of hemorrhagic outcomes in patients with smaller lesions.
This does not offer robust evidence to withhold or delay
anticoagulation among patients with larger lesions, for whom
risks and benefits may both be greater.
The results reported for the 3 NOACs in this study do not
provide an unbiased comparison in terms of efficacy and
safety. Consequently, the differences among NOACs are of
very limited value because the analysis was not adjusted. The
recent trend in analyzing the results of prospective nonran-
domized studies is to avoid “sensitive” comparisons and to
simply report the crude data, as we have done.26–29
In the RAF-NOACs study, 10% of the patients received
LMWH before NOACs. We found that these patients had a
significantly higher rate of bleeding events compared with
patients treated with oral anticoagulants alone. Patients who
received LMWH were likely patients with more severe stroke
Table 7. Characteristics of the Patients Treated or Not With
LMWH Before Oral Anticoagulants
Not Treated
With LMWH
(n=1050)
Treated With
LMWH
(n=111) P Value
Age, y 75.79.9 74.010.0
Sex, male 473 (45.0) 64 (57.6) 0.012
NIHSS on admission 7.56.0 8.57.1
Diabetes mellitus 201 (19.1) 21 (18.9)
Hypertension 805 (76.7) 79 (71.2)
Hyperlipidemia 369 (35.1) 40 (36.0)
Paroxysmal atrial fibrillation 513 (48.9) 52 (46.8)
History stroke/TIA 272 (25.9) 31 (27.9)
Current smoker 117 (11.1) 14 (12.6)
Alcoholism 66 (6.3) 7 (6.3)
History congestive heart failure 164 (15.6) 15 (13.5)
History myocardial infarction 119 (11.3) 14 (12.6)
Lesion size*
Small 409 (41.6) 40 (36.7)
Leukoaraiosis 615 (58.6) 60 (54.0)
CHA2DS2-VASc score after index stroke
>4 782 (74.5) 75 (68.7)
Data are shown as meanSD or n (%). LMWH indicates low-molecular-weight heparin;
NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack.
*1063 patients.
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
DOI: 10.1161/JAHA.117.007034 Journal of the American Heart Association 10
The RAF NOAC Study Paciaroni et al
D
ow
nloaded from
 http://ahajournals.org by on March 25, 2019
who were more likely to have dysphagia and perhaps to be at
inherently greater risk of adverse outcomes. It also appears
likely that LMWH may have been initiated earlier than NOACs,
at a time when there was an inherently much higher rate of
ischemic and hemorrhagic events, regardless of treatment
allocation.30 We think that considering the similar pharma-
cokinetics of NOACs and LMWH, it is not recommended to
start with LMWH before NOACs.
Our study had several limitations. First, the reported
associations in our nonrandomized study were potentially
influenced by numerous potential confounders. For this
reason, the conclusions should not be applied in a general-
ized manner but instead used on a case-by-case basis.
Second, the number of study outcome events was low,
limiting the statistical power of our analyses. Most important,
we cannot exclude the possibility that there might have been
selection bias regarding the starting time of antithrombotic
therapy. In fact, most patients who were either older adults
or who had severe stroke were not given treatment or
received treatment later compared with more stable patients.
However, clinical decisions must be made for patients with
nonvalvular AF after stroke, and our data may help inform
choices on timing and agent and may prompt a more formal
randomized study.
In conclusion, in patients with acute stroke and AF,
treatment with NOACs was associated with a 5% combined
rate for ischemic embolic recurrence and severe bleeding
within 90 days. Furthermore, composite rates of recurrence
and major bleeding were 12.4% in patients who initiated
NOACs within 2 days after acute stroke, 2.1% in those who
initiated NOACs between 3 and 14 days, and 9.1% in patients
who initiated NOACs >14 days after acute stroke. Future
randomized studies to assess timing of initiation and choice of
agent in patients with acute stroke and AF are warranted.
Table 8. Outcomes Events According to Lesion Size
Small (n=448) Medium (n=388) Large Anterior (n=180) Large Posterior (n=76)
Combined end point* 19 (4.2) 22 (5.7) 8 (4.4) 2 (2.6)
Ischemic stroke 10 (2.2) 8 (2.1) 1 (0.6) 1 (1.3)
Symptomatic hemorrhagic transformation 3 (0.7) 10 (0.3) 4 (2.2) 0
Stroke, TIA, or systemic embolism 13 (2.9) 10 (2.6) 4 (2.2) 1 (1.3)
Symptomatic hemorrhagic transformation,
severe extracranial bleeding
7 (1.6) 13 (3.4) 4 (2.2) 1 (1.3)
Data are shown as n (%). TIA indicates transient ischemic attack.
*Combined end point: symptomatic hemorrhagic transformation, ischemic stroke, TIA, systemic embolism and severe extracranial bleeding.
Figure 8. Cumulative risks of ischemic or hemorrhagic outcome events in patients with small vs
medium/large lesions.
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